Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

Johnson & Johnson announced Phase 3 PROTEUS study results showing ERLEADA® (apalutamide) combined with hormone therapy before and after prostate cancer surgery significantly reduces metastasis/death risk by 20% and increases pathologic complete response rates 9-fold compared to hormone therapy alone in patients with high-risk localized or locally advanced prostate cancer. The findings were presented at ASCO 2026 and published in The New England Journal of Medicine.